Auxilium Pallacanestro Torino

Wealth Management Industry Embraces an AI-Powered Future of Abundance and Growth at Fearless Investing Summit in Miami

Retrieved on: 
Tuesday, October 3, 2023
Technology, Finance, Fintech, Consulting, Banking, Professional Services, Software, Data Analytics, Asset Management, Artificial Intelligence, Kraken, Auxilium, Insurance, Lead management, RIA, Reward, Fearless, Documentation, Risk, CRMS, The White Glove, Auxilium Pallacanestro Torino, Growth, CIO, AI, Salesforce, FMG, Financial adviser, Pharmaceutical industry, Nitrogen

Nitrogen (formerly Riskalyze), the company that is revolutionizing how financial advisors and wealth management firms grow, today announced major enhancements to its growth platform and painted a cohesive vision of the AI-powered future of abundance for advisors at the company’s annual Fearless Investing Summit .

Key Points: 
  • Nitrogen (formerly Riskalyze), the company that is revolutionizing how financial advisors and wealth management firms grow, today announced major enhancements to its growth platform and painted a cohesive vision of the AI-powered future of abundance for advisors at the company’s annual Fearless Investing Summit .
  • The event brings together leaders from firms representing thousands of advisors from across the wealth management industry as well as the entire spectrum of supporting wealthtech.
  • “The conversation and community at the Fearless Investing Summit this week reinforced my belief that we’re at a huge and exciting inflection point as a wealth management profession,” said Aaron Klein , chief executive officer at Nitrogen.
  • For more information or for a demo of the Nitrogen Growth Platform, please visit NitrogenWealth.com/growth-platform .

ARS Pharmaceuticals Appoints Eric Karas as Chief Commercial Officer and Kathleen Scott as Chief Financial Officer

Retrieved on: 
Tuesday, April 5, 2022
Biotechnology, Pharmaceutical, Health, Medical Supplies, Auxilium, Industry, Company, University, CFA, Michigan State University, Endo International, Anaphylaxis, Marketing, University of California, San Francisco, Growth, Caregiver, Biting, Auxilium Pallacanestro Torino, YMCA, Rutgers University, Bristol Myers Squibb, Adrenaline, Kathy, Emergent, ARS, Government, Naloxone, Public relations, Allergy, MBA, Strategic planning, CPA, ARS-1, HCPS, Awareness, Accounting, RA, Food, Corporation, Patient, Disease, Pharmaceutical industry, Astellas Pharma, Merck

ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with the appointments of industry veterans, Eric Karas as chief commercial officer and Kathleen (Kathy) Scott as chief financial officer.

Key Points: 
  • ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with the appointments of industry veterans, Eric Karas as chief commercial officer and Kathleen (Kathy) Scott as chief financial officer.
  • Eric Karas, chief commercial officer, is a recognized commercial leader in the biopharmaceutical industry with more than 25 years of sales, marketing, market access and strategic planning experience across multiple specialty product launches.
  • Kathy Scott, chief financial officer, brings over 30 years of experience in accounting, auditing, financings and mergers and acquisitions.
  • Ms. Scott was previously the chief financial officer for various life science companies, including Neurana Pharmaceuticals, Recros Medica, Adigica Health, Clarify Medical, Oncternal Therapeutics, MDRejuvena and BioSurplus.